Table 1.
Pharmacological strategies to inhibit glutamine metabolism in cancer cells
| Class | Drug | Status | Ongoing clinical trials | |
|---|---|---|---|---|
|
| ||||
| Cancer type | NCT number | |||
| SLC1A5 inhibitor | GPNA | Preclinical tool | - | - |
| γ-FBP | ||||
| Benzylserine | ||||
| GLS inhibitors | BPTES | Preclinical tool | - | - |
| CB-839 | Phase I clinical | Hematologic tumors | NCT02071888 | |
| Solid tumors (TNBC, NSCLC, RCC, Mesothelioma…) |
NCT02071862 NCT02771626 |
|||
| 968 | Preclinical tool | |||
| GLUD inhibitor | EGCG | Preclinical study | Colorectal Cancer (not yet open for participants recruitment) | NCT02891538 |
| R162 | Preclinical tool | - | - | |
| Aminotransferase inhibitors | AOA | Clinically used to treat tinnitus | - | - |
GPNA: Benzylserine and L-γ-gluatamyl-p-nitroanilide, γ-FBP: γ-folate binding protein, GLS: glutaminase, BPTES: bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide, TNBC: Triple-negative Breast Cancer, NSCLC: Non Small Cell Lung Cancer, RCC: Renal Cell Carcinoma, GLUD: glutamate dehydrogenase, EGCG: pigallocatechin gallate, AOA: aminooxyacetate.